FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma

NEXT STORY
Palette Life Sciences Announces Completion of $30 Million Equity Financing and Expansion of the Board of Directors
PREV STORY
The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Sanofi and Lonza Enter into a Strategic Partnership to Establish a Large-Scale Biologics Production Facility

Sanofi and Lonza Enter into a Strategic Partnership to Establish a Large-Scale Biologics Production ...

author_avatar
NASDAQ Market News

BriaCell to Hold Conference Call on Key Clinical Findings; Activities

BERKELEY, Calif. and VANCOUVER, British Columbia, June 21, 2018 (GLOBE NEWSWIRE) -- BriaCell Therapeutics ...

author_avatar
NASDAQ Market News

Global $800+ Mn Viral Vector Manufacturing Market to 2023

Dublin, Jan. 02, 2019 (GLOBE NEWSWIRE) -- The "Viral Vector Manufacturing Market by Type, ...

author_avatar
NASDAQ Market News